Approach to the patient: concept and application of targeted radiotherapy in the paraganglioma patient

K Pacak, D Taieb, FI Lin, A Jha - The Journal of Clinical …, 2024 - academic.oup.com
Paragangliomas can metastasize, posing potential challenges both in symptomatic
management and disease control. Systemic targeted radiotherapies using 131I-MIBG and …

[HTML][HTML] MAML3-fusions modulate vascular and immune tumour microenvironment and confer high metastatic risk in pheochromocytoma and paraganglioma

M Monteagudo, B Calsina, ME Salazar-Hidalgo… - Best Practice & …, 2024 - Elsevier
Pheochromocytomas and paragangliomas are rare neuroendocrine tumours. Around 20-
25% of patients develop metastases, for which there is an urgent need of prognostic markers …

[HTML][HTML] PD-L1 expression is linked to tumor-infiltrating T-cell exhaustion and adverse pathological behavior in pheochromocytoma/paraganglioma

A Yu, X Xu, Y Pang, M Li, J Luo, J Wang, L Liu - Laboratory Investigation, 2023 - Elsevier
Pheochromocytoma/paraganglioma (PPGL) is an endocrine-related tumor associated with
excessive catecholamine release and has limited treatment options once metastasis occurs …

Overview of recent guidelines and consensus statements on initial screening and management of phaeochromocytoma and paraganglioma in SDHx pathogenic …

C Lussey-Lepoutre, K Pacak, A Grossman… - Best Practice & …, 2024 - Elsevier
Phaeochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours with
a strong genetic predisposition, involving over 20 genes and with germline pathogenic …

Molecular classification and tumor microenvironment characteristics in pheochromocytomas

S Qin, Y Xu, S Yu, W Han, S Fan, W Ai, K Zhang… - Elife, 2024 - elifesciences.org
Pheochromocytomas (PCCs) are rare neuroendocrine tumors that originate from chromaffin
cells in the adrenal gland. However, the cellular molecular characteristics and immune …

The Molecular Classification of Pheochromocytomas and Paragangliomas: Discovering the Genomic and Immune Landscape of Metastatic Disease

CJM de Bresser, RR de Krijger - Endocrine Pathology, 2024 - Springer
Abstract Pheochromocytomas (PCCs) and paragangliomas (PGLs, together PPGLs) are the
most hereditary tumors known. PPGLs were considered benign, but the fourth edition of the …

Immunotherapy for endocrine tumours: A clinician's perspective

A Angelousi, P Tzoulis, M Tsoli… - Endocrine-Related …, 2024 - erc.bioscientifica.com
Immunotherapy has revolutionised the treatment of oncological patients, but its application
in various endocrine tumours is rather limited and is mainly used when conventional …

A comprehensive characterisation of phaeochromocytoma and paraganglioma tumours through histone protein profiling, DNA methylation and transcriptomic analysis …

P Chatzikyriakou, D Brempou, M Quinn, L Fishbein… - Clinical …, 2023 - Springer
Abstract Background Phaeochromocytomas and paragangliomas (PPGLs) are rare
neuroendocrine tumours. Pathogenic variants have been identified in more than 15 …

Regulation of epinephrine biosynthesis in HRAS-mutant paragangliomas

M Li, S Richter, H Mohr, S Drukewitz… - Endocrine-related …, 2023 - erc.bioscientifica.com
The biochemical phenotype of paragangliomas (PGLs) is highly dependent on the
underlying genetic background and tumor location. PGLs at extra-adrenal locations usually …

The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives

O Uher, K Hadrava Vanova, D Taïeb… - Endocrine …, 2024 - academic.oup.com
Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors derived
from neural crest cells from adrenal medullary chromaffin tissues or extra-adrenal …